Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Here, we show the activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in a MMTV-CreBrca1(f/f)Trp53(+/-) mouse model of breast cancer.
|
22915751 |
2012 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In our study, PIK3CA mutations were related to good and moderate prognosis in breast cancer patients.
|
27901576 |
2017 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
And PIK3CA mutations alone may have limited prognostic value for HR-positive BCa patients.
|
25176561 |
2014 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Collectively, these results suggest that PIP5Kα is a novel degradative substrate of NEDD4 and that the PIP5Kα-dependent PIP2 pool contributing to breast cancer cell proliferation through PI3K/Akt activation is negatively controlled by NEDD4.
|
29851245 |
2018 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Furthermore, GSK3β can regulate cell viability through the PTEN/PI3K/AKT signaling pathway and induce chemoresistance, serving as a valuable molecular strategy for breast cancer therapy.
|
31006103 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings demonstrated that the IL-22-HOXB-AS5-PI3K/AKT functional axes may serve as potential molecule biomarkers for diagnosis and therapy evaluation or targeted therapeutic strategy in BC.
|
29262587 |
2017 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alpelisib (Piqray™)-an orally available phosphatidylinositol 3-kinase (PI3K) inhibitor with specific activity against PI3K alpha (PI3Kα)-is being developed by Novartis for the treatment of breast cancer.
|
31256368 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
More recently PIK3CA mutations have been shown to induce tumor heterogeneity and are associated with activation of EGFR-signaling and reduced relapse free survival in basal subtype of breast cancer.
|
27941987 |
2016 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results indicated that miR-1297 functioned as an oncogene in regulating the proliferation, cell cycle and apoptosis of BC via targeting PTEN/PI3K/AKT signaling, and may represent a novel potential therapeutic target and prognostic marker for BC.
|
28791363 |
2017 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We firstly provided evidence that LHX6 exerted its anti-tumor function on BC via suppressing activation of the PI3K/Akt/mTOR signaling, which eventually inhibited the progression of BC.
|
29863252 |
2018 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA hotspot mutations are present at a relatively high frequency in CTCs and their presence is associated with worse survival in patients with breast cancer with metastasis.
|
25398847 |
2014 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
|
26289070 |
2015 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Previous work has shown that prostate cancer in a Pten-null murine model is dependent on the p110β isoform of phosphatidylinositol 3-kinase (PI3K), while breast cancer driven by either polyoma middle T antigen (MT) or HER2 is p110α dependent.
|
24991009 |
2014 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Conclusively, this study shed lights on the effect of PI3K inhibition in chemo-sensitivity of MCF-7 cells, disclosing that combination of BKM120 and ATO could be a promising therapeutic approach in BC.
|
31539632 |
2019 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer.
|
30454896 |
2018 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Genetic changes in HER2, PTEN, PIK3CA and AKT1 are all common in breast cancer and lead to the elevated phosphorylation of downstream targets of the PI3K/AKT signalling pathway.
|
23085752 |
2013 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that mutations of PIK3CA play an oncogenic role in substantial fractions of ovarian and breast carcinomas, and in consideration of mutation of other components of the PI3K-AKT pathway in both tumor types, confirm the major oncogenic role of this pathway in ovarian and breast carcinomas.
|
15837735 |
2005 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT is a major pathway involved in the regulation of cell survival and proliferation, and is the most frequently altered pathway in breast cancer, apparently with different biologic impact on specific cancer subtypes.
|
26540293 |
2015 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, our findings show that triple negative breast cancers with apocrine differentiation constitute a distinct subset, characterized by a high frequency of PI3K pathway alterations similar to luminal subtypes of breast cancer.
|
26939876 |
2016 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We find mutually exclusive associations between EECTGs and somatic mutations in mutated genes, such as PIK3CA in breast cancer.
|
26813108 |
2016 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer.
|
27211281 |
2016 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Contrarily, the finding for the MTOR gene and breast cancer is biologically plausible because the MTOR protein plays an important role in PI3K/Akt signaling, which is a pathway related to cancer development and cell senescence.
|
30678711 |
2019 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.
|
25036402 |
2014 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Binding of MMP-9-degraded fibronectin to β6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer.
|
26134759 |
2015 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations frequently occur in ERα-positive breast cancer and result in PI3K/AKT/mTOR activation in vitro.
|
24467828 |
2014 |